<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9E6E29A1-FFE3-487C-84F6-02CD1B6E313A"><gtr:id>9E6E29A1-FFE3-487C-84F6-02CD1B6E313A</gtr:id><gtr:name>National Institute for Biological Standards and Control (NIBSC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/453DB5AB-8BFE-4E0A-B761-1C39BD880D5D"><gtr:id>453DB5AB-8BFE-4E0A-B761-1C39BD880D5D</gtr:id><gtr:name>Scripps Research Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BC911109-1671-4D57-BF27-8F8A86FF2D10"><gtr:id>BC911109-1671-4D57-BF27-8F8A86FF2D10</gtr:id><gtr:name>HUMABs Biomed, Bellinzona,Switzerland</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F5914C2A-6AE8-4A26-ACA8-99C3D6D87514"><gtr:id>F5914C2A-6AE8-4A26-ACA8-99C3D6D87514</gtr:id><gtr:name>University of Melbourne</gtr:name><gtr:address><gtr:line1>University of Melbourne</gtr:line1><gtr:line2>Melbourne Research Office</gtr:line2><gtr:line3>Parkville</gtr:line3><gtr:line4>Melbourne</gtr:line4><gtr:line5>Victoria</gtr:line5><gtr:postCode>3010</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4C6CADA1-1825-4102-82B3-3E25082120D5"><gtr:id>4C6CADA1-1825-4102-82B3-3E25082120D5</gtr:id><gtr:name>EBOVAC2 Consortium</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2F6044B9-9BC3-4ABA-9115-6AA15854A44A"><gtr:id>2F6044B9-9BC3-4ABA-9115-6AA15854A44A</gtr:id><gtr:name>University of Basel</gtr:name><gtr:address><gtr:line1>Petersplatz 1</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9E6E29A1-FFE3-487C-84F6-02CD1B6E313A"><gtr:id>9E6E29A1-FFE3-487C-84F6-02CD1B6E313A</gtr:id><gtr:name>National Institute for Biological Standards and Control (NIBSC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/453DB5AB-8BFE-4E0A-B761-1C39BD880D5D"><gtr:id>453DB5AB-8BFE-4E0A-B761-1C39BD880D5D</gtr:id><gtr:name>Scripps Research Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BC911109-1671-4D57-BF27-8F8A86FF2D10"><gtr:id>BC911109-1671-4D57-BF27-8F8A86FF2D10</gtr:id><gtr:name>HUMABs Biomed, Bellinzona,Switzerland</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F5914C2A-6AE8-4A26-ACA8-99C3D6D87514"><gtr:id>F5914C2A-6AE8-4A26-ACA8-99C3D6D87514</gtr:id><gtr:name>University of Melbourne</gtr:name><gtr:address><gtr:line1>University of Melbourne</gtr:line1><gtr:line2>Melbourne Research Office</gtr:line2><gtr:line3>Parkville</gtr:line3><gtr:line4>Melbourne</gtr:line4><gtr:line5>Victoria</gtr:line5><gtr:postCode>3010</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4C6CADA1-1825-4102-82B3-3E25082120D5"><gtr:id>4C6CADA1-1825-4102-82B3-3E25082120D5</gtr:id><gtr:name>EBOVAC2 Consortium</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2F6044B9-9BC3-4ABA-9115-6AA15854A44A"><gtr:id>2F6044B9-9BC3-4ABA-9115-6AA15854A44A</gtr:id><gtr:name>University of Basel</gtr:name><gtr:address><gtr:line1>Petersplatz 1</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/65AF1713-F5D3-41D8-A71A-DA5E41A4F797"><gtr:id>65AF1713-F5D3-41D8-A71A-DA5E41A4F797</gtr:id><gtr:firstName>Vincenzo</gtr:firstName><gtr:surname>Cerundolo</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UU_12010%2F1"><gtr:id>65752A2D-C8D0-4F25-A228-2C3F9EB625F5</gtr:id><gtr:title>Cross-talk between innate and adaptive immune responses in the optimization of cancer vaccination strategies</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UU_12010/1</gtr:grantReference><gtr:abstractText>We are pursuing several different lines of investigation with the common goal of improving treatment strategies for cancer. The ability of cancer cells to avoid destruction by the immune system means that as yet there is no effective treatment. We know that in several different types of cancer there are increased numbers of cells called myeloid suppressor cells (MDSC) that suppress the immune system, and therefore allow cancer cells to continue to grow and divide. We also know that another kind of immune cells - invariant natural killer T (iNKT) cells ?monitor malignant cells and decrease the numbers of circulating MDSCs in melanoma patients, thus restoring the immune response to cancer cells. These iNKT cells are very important because they form a ?bridge? between the part of the immune system that recognises foreign proteins and the part that destroys abnormal cells. By studying the behaviour of iNKT cells we aim to find ways of increasing their activity in a controlled way, and use them to ?jump-start? immune responses to tumour cells. Our clinical trial program is presently translating preclinical findings into phase I and II clinical trials of cancer vaccine candidates.</gtr:abstractText><gtr:technicalSummary>Goals To develop vaccination strategies to enhance tumour specific T cell responses. By bridging the innate and adaptive arms of the immune system invariant NKT (iNKT) cells can be harnessed to jump-start antigen-specific immune responses. Stimulation of iNKT cells in vivo with the specific synthetic ligands results in significantly enhanced immune responses to protein-based vaccines. Further, activation of human dendritic cells (DC) by toll-like receptor (TLR) agonists modulates the lipid biosynthetic pathway, resulting in enhanced recognition of CD1d associated lipids by iNKT cells. Thus, iNKT cells significantly influence the efficacy of immune responses to soluble antigen by modulating DC function, supporting the concept that there is substantial immunostimulatory power in the integration of iNKT cell- and TLR-mediated signals to dendritic cells. We have characterized by structural (1), kinetic (2), and functional (2,3) studies a novel family of NKT cell agonists (4), and more recently shown that iNKT cells modulate the suppressive activity of neutrophils (5). A large proportion of melanoma cells produces the major acute-phase reactant serum amyloid A-1 (SAA-1), one of the first and most abundant proteins secreted during the physiological response to infection and injury. By binding to formyl-peptide receptor 2 expressed by neutrophils, SAA induces them to secrete IL-10 which suppresses the T cell response. CD1d- and CD40- dependent interaction of neutrophils with iNKT cells ameliorates this suppressive activity indicating a pivotal role anti-tumour responses (5). Tumours also evade immune responses by depleting tryptophan via the tryptophan catabolizing enzyme indoleamine 2,3 dioxygenase (IDO). Such depletion induces regulatory T cells and inhibits effector T cells. Local tryptophan depletion is overcome by IDO positive tumour cells by the expression of a novel amino acid transporter distinct from system L (6) - this increases tryptophan entry into IDO positive tumours, depleting the microenvironment further. This additional tryptophan transporter could be the key to pharmacological inhibition of IDO mediated tumour escape (6). The ability to direct homing of antigen specific T cells to specific tumour tissue is crucial to anti-tumour strategies. We have extended the notion that production of retinoic acid (RA) by dendritic cells (DCs) is critical for development of gut-tropic immune responses by demonstrating that Prostaglandin E2 blocks expression of retinal dehydrogenases (RALDH) - enzymes responsible for converting vitamin A into RA - abrogating the ability to induce CCR9 expression upon T cell priming (7). Future research plans Future work aims to characterize further strategies to enhance immune responses and to modify the tumour microenvironment, with emphasis on: (a) the role of iNKT cells in bridging the adaptive and innate immune responses; (b) the plasticity of myeloid cells in regulating tumour specific immune responses; (c) the role of tryptophan degrading enzymes in upregulating higher affinity tryptophan transporters; and (d) vaccine clinical trials in melanoma patients. References: (1) Koch et al. 2005 Nature Immunol 6: 819 (2) McCarthy et al 2007 J Exp Med 204: 1131 (3) Salio et al 2007 Proc Natl Acad Sci 104:20490 (4) Silk et al 2008 J Immunol 180: 6452 (5) De Santo et al 2010 Nature Immunol 11: 1039 (6) Silk et al 2011 J Immunol 187: 1617 (7) Stock et al 2011 J Exp Med 208: 761.</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>4634000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>HUMABs Biomed, Bellinzona,Switzerland</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>Collaboration with HUMABs, Switzerland</gtr:description><gtr:id>1D92BF77-F98C-4491-9F4F-3578E8668D82</gtr:id><gtr:impact>No published outcome yet</gtr:impact><gtr:outcomeId>58c7ed22089db2.27494506-1</gtr:outcomeId><gtr:partnerContribution>Collaborative project and supply of antibodies</gtr:partnerContribution><gtr:piContribution>Isolation of a cocktail of neutralizing antibodies from vaccinees to compare with the ZMapp cocktail derived from murine antibodies</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Harvard Medical School</gtr:department><gtr:description>Collaboration with Harvard University</gtr:description><gtr:id>99671848-47E9-48CF-8A06-C8668F1C4588</gtr:id><gtr:impact>Publications of papers in peer-reviewed journals.</gtr:impact><gtr:outcomeId>58c91545bcc387.57324272-1</gtr:outcomeId><gtr:partnerContribution>Collaborative project</gtr:partnerContribution><gtr:piContribution>Analysis of CD1 restricted Salmonella-specific T cell responses</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Scripps Research Institute</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Collaboration with the Viral Hemorrhagic Fever Immunotherapeutic Consortium</gtr:description><gtr:id>F6154D89-CB85-4EA8-84D0-7EA610C86746</gtr:id><gtr:impact>No published outcome yet</gtr:impact><gtr:outcomeId>58c7ec5e3a4435.00735189-1</gtr:outcomeId><gtr:partnerContribution>Collaborative project and supply of antibodies</gtr:partnerContribution><gtr:piContribution>Isolation of a cocktail of neutralizing antibodies from vaccinees to compare with the ZMapp cocktail derived from murine antibodies</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UCB Pharma</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with UCB Celltech</gtr:description><gtr:id>C4374E13-CD41-422E-BFE3-56491F4657F3</gtr:id><gtr:impact>No published outcome yet</gtr:impact><gtr:outcomeId>58c7ee82200c53.74695722-1</gtr:outcomeId><gtr:partnerContribution>Collaborative project</gtr:partnerContribution><gtr:piContribution>Isolation of a cocktail of neutralizing antibodies from vaccinees to compare with the ZMapp cocktail derived from murine antibodies</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Medicine</gtr:department><gtr:description>Role of novel scavenger receptor in inflammatory responses of human airways</gtr:description><gtr:id>26E19D52-AFAC-4EF2-A874-541FE3A02BA4</gtr:id><gtr:impact>These collaborative studies are in progress but we anticipate peer-reviewed publication(s) derived from these studies within the next twelve months.</gtr:impact><gtr:outcomeId>5F0312A7D77-1</gtr:outcomeId><gtr:partnerContribution>In collaboration with Professor Donna Davies and Dr Marina Leino we are exploring the expression and biological activities of the novel scavenger receptor in the inflammatory responses of ex-vivo airway tissues from healthy and diseased donors.</gtr:partnerContribution><gtr:piContribution>We have provided expertise and knowledge as well as specific reagents to the collaboration to facilitate the studies of patient material obtained through clinical consultations</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cancer Research UK London Research Institute (LRI)</gtr:department><gtr:description>B cell biology and NKT cells</gtr:description><gtr:id>594C5398-F87D-4E14-B27A-A4E1898B0641</gtr:id><gtr:impact>Publications:
20228797
18550831</gtr:impact><gtr:outcomeId>miVV76zRHLH-1</gtr:outcomeId><gtr:partnerContribution>Collaborative work on the interaction of the innate and adaptive immune responses has led to two publications. The collaborator studies the role of B cells in this interaction.</gtr:partnerContribution><gtr:piContribution>Collaborative work on the interaction of the innate and adaptive immune responses has led to two publications. We study the role of NKT cells in this interaction.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Basel</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Biozentrum Basel</gtr:department><gtr:description>Collaboration with Professor Dirk Bumann</gtr:description><gtr:id>62B59A5C-7420-4DE8-A2A5-1A4315B23B67</gtr:id><gtr:impact>No published outcome yet</gtr:impact><gtr:outcomeId>58c7f37c01e501.09201982-1</gtr:outcomeId><gtr:partnerContribution>Collaborative project</gtr:partnerContribution><gtr:piContribution>Use of libraries of Salmonella specific T cell clones generated from Salmonella infected volunteers to identify and characterize cross-reactive and serovar specific Salmonella T cell antigens</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with Professor Gordon Dougan</gtr:description><gtr:id>B4D57A2C-6302-46F2-B0B7-CACFF50E4DA2</gtr:id><gtr:impact>No published outcome yet</gtr:impact><gtr:outcomeId>58c7f275ab88a5.01157751-1</gtr:outcomeId><gtr:partnerContribution>Collaborative project</gtr:partnerContribution><gtr:piContribution>Use of libraries of Salmonella specific T cell clones generated from Salmonella infected volunteers to identify and characterize cross-reactive and serovar specific Salmonella T cell antigens</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Molecular Haematology Unit</gtr:department><gtr:description>Collaboration with the MRC Molecular Haematology Unit</gtr:description><gtr:id>5D0153FB-7D47-430D-B2A1-0C1F8E8BFFB1</gtr:id><gtr:impact>No published outcomes yet</gtr:impact><gtr:outcomeId>58c92fa2981104.21039628-1</gtr:outcomeId><gtr:partnerContribution>Collaborative project</gtr:partnerContribution><gtr:piContribution>We are studying how nutritional stress alters the transcriptomic profile of AML blasts and T lymphocytes</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Oxford Vaccine Group</gtr:department><gtr:description>Collaboration with the Oxford Vaccine Group</gtr:description><gtr:id>6B9BFBB2-D2B2-4749-9B60-0E9CE22C760A</gtr:id><gtr:impact>Collaboration still ongoing</gtr:impact><gtr:outcomeId>56deab019ea719.34225520-1</gtr:outcomeId><gtr:partnerContribution>As a joint collaboration, we are investigating disease mechanisms in enteric fever to characterise innate and adaptive immunity in mucosa and blood in controlled human infection models</gtr:partnerContribution><gtr:piContribution>In the context of the MRC Experimental Medicine Challenge Grant, my group has set up a close collaboration with the Oxford Vaccine Group directed by Professor Andrew Pollard.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Pharmacology</gtr:department><gtr:description>Role of lysosome in activation of specific pattern recognition receptors</gtr:description><gtr:id>7662E458-351C-4E16-8AE8-30228F2844BC</gtr:id><gtr:impact>This collaboration has resulted in the obtaining of a grant from a US based charity to financially support one aspect of the study and the results obtained to date are the basis of a recently-submitted grant application to MRC. An undergraduate project student is currently contributing to this research and a manuscript is in preparation.</gtr:impact><gtr:outcomeId>L18DUW2vGoF-1</gtr:outcomeId><gtr:partnerContribution>Provision of expertise, animal models, co-writing of grant application that led to additional grant funding, co-applicant on successful application to industrial collaborator for provision of llcensed biologic drug which will be tested in the animal models.</gtr:partnerContribution><gtr:piContribution>Made a novel observation of aberrant activation of a pro-inflammatory innate immune mechanism in a mouse model of a glycosphingolipid storage disease.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Melbourne</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Collaboration with Professor Dick Strugnell</gtr:description><gtr:id>0048EEEC-1E82-4080-9099-0E0C0D53315E</gtr:id><gtr:impact>No published outcome yet</gtr:impact><gtr:outcomeId>58c7f3d3cdcf83.85847357-1</gtr:outcomeId><gtr:partnerContribution>Collaborative project</gtr:partnerContribution><gtr:piContribution>Use of libraries of Salmonella specific T cell clones generated from Salmonella infected volunteers to identify and characterize cross-reactive and serovar specific Salmonella T cell antigens</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Biological Standards and Control (NIBSC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with NIBSC</gtr:description><gtr:id>2B4D83B2-E697-4157-9F37-05AA2DCCB8C4</gtr:id><gtr:impact>No published outcome yet</gtr:impact><gtr:outcomeId>58c7ee38973702.97215108-1</gtr:outcomeId><gtr:partnerContribution>Collaborative project</gtr:partnerContribution><gtr:piContribution>Isolation of a cocktail of neutralizing antibodies from vaccinees to compare with the ZMapp cocktail derived from murine antibodies</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>EBOVAC2 Consortium</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Collaboration with EBOVAC2</gtr:description><gtr:id>FCF1F9D0-6DFB-4233-86EA-EA56DE0232CA</gtr:id><gtr:impact>No published outcome yet</gtr:impact><gtr:outcomeId>58c7ededdcb6f7.64681031-1</gtr:outcomeId><gtr:partnerContribution>Collaborative project and search through B cells of donors</gtr:partnerContribution><gtr:piContribution>Isolation of a cocktail of neutralizing antibodies from vaccinees to compare with the ZMapp cocktail derived from murine antibodies</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Structural Biology</gtr:department><gtr:description>Collaboration with Professor Yvonne Jones' Group</gtr:description><gtr:id>EF2F3220-588E-40D7-97A3-FB0D3CAF0850</gtr:id><gtr:impact>No published outcomes yet</gtr:impact><gtr:outcomeId>58c92f28c51ac4.99461402-1</gtr:outcomeId><gtr:partnerContribution>Collaborative project</gtr:partnerContribution><gtr:piContribution>We are developing a collaboration on the role of semaphorins in hampering T cell responses</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Public Health England</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with Public Health England</gtr:description><gtr:id>76815739-E2DE-4C2D-9DC3-D7FB2596A96C</gtr:id><gtr:impact>No published outcome yet</gtr:impact><gtr:outcomeId>58c7ed8647c520.45925239-1</gtr:outcomeId><gtr:partnerContribution>Collaborative project</gtr:partnerContribution><gtr:piContribution>Isolation of a cocktail of neutralizing antibodies from vaccinees to compare with the ZMapp cocktail derived from murine antibodies</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with Professor Sarah Teichmann</gtr:description><gtr:id>CF53CC66-CE7E-45AE-9FB4-9B8D0E622021</gtr:id><gtr:impact>No published outcome yet</gtr:impact><gtr:outcomeId>58c7f22871c1e4.42495727-1</gtr:outcomeId><gtr:partnerContribution>Collaborative project</gtr:partnerContribution><gtr:piContribution>Single cell RNAseq analysis of CD4 T cell responses to Salmonella Typhi and Paratyphi</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>John Humphrey Lecture Series, Immunology Department, Imperial College London 'Novel insights into the Biology of Human Toll-like Receptor 7'</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>0F3C8131-0A58-4808-AEE8-F3C7BE845A35</gtr:id><gtr:impact>Students and Scientific Peers attended my talk, which was followed by meetings with members of the Faculty. This Improved the relations between our institutes.

Currently negotiating collaboration for a paper</gtr:impact><gtr:outcomeId>544f9d84118e07.22591224</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>https://www1.imperial.ac.uk/medicine/research/institutes/cipm/courses/jhss/</gtr:url><gtr:year>2011,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Harnessing invariant NKT cells to enhance antigen specific immune responses - Kennedy Seminar Series, University of Oxford</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>FBB5213F-2676-40CA-A6FB-805272272F27</gtr:id><gtr:impact>Students from the Kennedy Institute of Rheumatology attended the lecture, and the Q&amp;amp;A afterwards

Further requests for exchange of information between the units</gtr:impact><gtr:outcomeId>544fa90e481b71.80665283</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit by 50 students from the Utrecht Junior School, the Netherlands</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0C099731-13D4-4888-A393-9F4A472BB632</gtr:id><gtr:impact>A group of 50 students from Utrecht Junior College in the Netherlands took place in the WIMM and the MRC Human Immunology Unit. 100% of students who attended said that they both enjoyed the day and learnt something new about science.</gtr:impact><gtr:outcomeId>56dd826d6bbda8.15372859</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Publication of glossy brochure for dissemination</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9ABC024B-4CF4-4E2D-BB2E-03FF6D5F2C58</gtr:id><gtr:impact>Development and publication of a glossy brochure illustrating in lay terms the important work carried out in the unit and dissemination to the general public.</gtr:impact><gtr:outcomeId>58b6adbb37e217.62815398</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxford Alumni</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F0AFE288-05B9-4510-A315-E9F60B3445B2</gtr:id><gtr:impact>Prof. Cerundolo gave a lecture on tumour immunology and cancer vaccines to a group of 130 Oxford Alumni (average age 60 years)

Talk was well received</gtr:impact><gtr:outcomeId>oAzHzYGfm4T</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Ability of Invariant NKT cells to modulate the phenotype and function of antigen presenting cells - Ludwig Maximilians University, Germany</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>847CD0C3-EE98-4B79-9C27-6920A7255006</gtr:id><gtr:impact>Inited to give a lecture in Germany

More students inquiring about coming here to work/study</gtr:impact><gtr:outcomeId>544fa617144668.73784470</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invariant NKT cells at the interface between adaptative and innate immune response - Peter Gorer Dept of Immunobiology, King's College London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>37C492B6-F325-4FC3-8832-C4A48ED2B2CA</gtr:id><gtr:impact>80 Students attended the lecture and following Q&amp;amp;A session

Increase in requests about working/studying in my unit</gtr:impact><gtr:outcomeId>544faab78e4e29.10624263</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science evening at Eynsham Primary School</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>BE04E76E-1045-4878-8BB3-BEB61070AEBE</gtr:id><gtr:impact>A hands-on interactive science evening at a local primary school</gtr:impact><gtr:outcomeId>58b6a962c55ae3.56659664</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Festival of Medical Research</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>00537252-8A03-492B-8AEC-BC78B653930C</gtr:id><gtr:impact>To showcase and discuss the important work carried out in the Unit</gtr:impact><gtr:outcomeId>58b6a841510588.05134194</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Primary Science Day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>3DEA0C74-8585-4697-9276-B9BF5F91E869</gtr:id><gtr:impact>A day aimed at enriching students' studies of maths and science through a range of short hands-on workshops focusing on Chemistry, Materials Science, Physics and Maths.</gtr:impact><gtr:outcomeId>58b6a722a18c48.94781643</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Work experience visits by 5th &amp; 6th year students</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E1FE71F1-5683-4B5B-8225-F696FEB9BDAB</gtr:id><gtr:impact>Work experience visits to the MRC Human Immunology Unit by a total of 19 students in 2016.</gtr:impact><gtr:outcomeId>58b6aa041d0918.83906435</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Ability of Invariant NKT cells to modulate the phenotype and function of Myeloid cells - Roche Glycart AG, Schleren, Zurich, Switzerland</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B5CF264D-1AE2-4F96-8E4A-074475527526</gtr:id><gtr:impact>Gave a talk to research Scientists at Roche to enhance their knowledge of new advance in the field of inflammation, and participated in discussions about translational research.

In discussions about potential collaboration/funding</gtr:impact><gtr:outcomeId>5450ba86043ec5.19231508</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Microscopy goes to School</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>3DAEDBB2-1473-4A73-9F10-FDD8F5A3924D</gtr:id><gtr:impact>A novel, interactive workshop called &amp;quot;Microscopy Goes to School&amp;quot; was created to introduce the basic concepts of microscopy to young students (10-12 years old) and hopefully inspire an interest in science at an early age. The students learnt about fundamentals of light and optics, and they built simple microscopes using basic optical tools (lenses, boxes, lasers, lamps etc.)</gtr:impact><gtr:outcomeId>56d96a1fa634a8.12941008</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>OxHOS Roadshow in Wales</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A463A05C-1CFC-42A1-B284-3AE2DFE15211</gtr:id><gtr:impact>To raise awareness and interest in science by taking interactive, Hands-On experiments to schools and public venues.</gtr:impact><gtr:outcomeId>58b6a8bdc07139.62797512</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>A level student visits 2012</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>654F218E-ACF7-42D0-A537-59DB92FBFE87</gtr:id><gtr:impact>2 students were hosted by members of my group for a &amp;quot;work experience week'

school would like to repeat the program in 2013</gtr:impact><gtr:outcomeId>KJWK3GV3oJx</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Organisation of Half-day Public Engagement training session</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A9ED7195-B75C-44AF-A09D-B42FD823F419</gtr:id><gtr:impact>On Tuesday, September 16th from 10am to 1pm, I arranged with Science Oxford an in-depth half-day Public Engagement in Science training session for members of the MRC Human Immunology Unit, to foster greater interactions and assist members of the unit in developing outreach activities.</gtr:impact><gtr:outcomeId>56e0069810c928.76337675</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Work Experience students in the MRC Human Immunology Unit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3299AFBA-274C-4FDE-9D58-07B2F5B2C50E</gtr:id><gtr:impact>The PIs in the MRC Human Immunology Unit hosted a total of 11 young students (16 and 17 year olds) on a work experience placement of one or two weeks, with the aim of fostering an interest in a scientific career and raising awareness in the type of work carried out in the Unit</gtr:impact><gtr:outcomeId>56dd8013c8e516.04052173</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Magadalen College School</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8DD5B33D-A5A5-47C3-A8C5-8ED538C6EB95</gtr:id><gtr:impact>Prof. Cerundolo gave a lecture at Magadalen College School, Oxford to 130 17-year olds on the career path of scientists in which he described training and job opportunities in biomedical research

School interested in future visits</gtr:impact><gtr:outcomeId>PN3dP8aVT7M</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>Pre-2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School Work Experience</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E1B091D3-4D4E-44CA-83F1-4BE6548BADD7</gtr:id><gtr:impact>Where possible within the constraints of Health &amp;amp; Safety, the Unit welcomes sixth form students to carry out their work experience within the Unit - undertaking simple practical techniques and shadowing Unit members to get a better appreciation of a career in medical research. One student spent 1 week working in my Lab.

School asked for future opportunities</gtr:impact><gtr:outcomeId>GvNSLyxyXwc</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centenary Celebrations</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>29DE363C-0803-46DA-992A-C5426CFC8914</gtr:id><gtr:impact>The event was attended by approx. 2500 members of the public.

The event was extremely well received and raised awareness into the activities carried out by the MRC Units in Oxford and beyond.</gtr:impact><gtr:outcomeId>eCxjr99qZDP</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxford University Department for Continuing Education Human and Veterinary Vaccinology Course</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>18A9EFA0-2893-4F4B-A8D1-80FC98DB3FB7</gtr:id><gtr:impact>During the last 2 years, the Oxford University Department for Continuing Education http://www.conted.ox.ac.uk/courses/C900-1 
has launched a leading educational programme in Vaccinology, tailored to the needs of industry in the UK and beyond, by sharing the expertise of several investigators, both at the Institute for Animal Health and across the University of Oxford, complemented by the views and experience of distinguished outside speakers. The courses run in 2010 were fully subscribed and received very good feedback from the participants. The satisfaction scores were very high: 88% for the Human and Veterinary Vaccinology; 77% for the Clinical Vaccine Development course; and 81% for the Vaccine Biomanufacturing course.
In November 2011 Prof. Cerundolo gave a talk entitled 'An Introduction to Tumour Immunology'

Course was well attended</gtr:impact><gtr:outcomeId>AdujC2g5L82</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Ability of Invariant NKT cells to modulate the phenotype and function of Myeloid cells - Institute for Immunity Transplantation and Infection, Stanford University, USA</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>483DB167-F45F-4714-87E8-877B5B51CB9D</gtr:id><gtr:impact>150 Medical and research based Postgraduates and their lead Scientists attended the Seminar and following Q&amp;amp;A session

n/a</gtr:impact><gtr:outcomeId>5450bc818d98e4.53057235</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxfordshire Science Festival</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>EA91DC79-FC07-44BD-9213-48ACD38522B7</gtr:id><gtr:impact>To showcase our multi-disciplinary department through interactive demonstrations and hands-on activities.</gtr:impact><gtr:outcomeId>58b6a7b3c99473.12646672</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invariant NKT cells at the interface between adaptative and innate immune response - Edinburgh Immunology Group, University of Edinburgh</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D52F9F01-A690-46C6-B2A1-290B7C3C430E</gtr:id><gtr:impact>Lecture given to The Edinburgh Immunology Group, University of Edinburgh, followed by informal discussions with the scientists

Currently setting up grant proposal for a new collaboration with Scientists from Edinburgh</gtr:impact><gtr:outcomeId>544faedc1ab165.76565962</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>880000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Community Research and Development Information Service (CORDIS)</gtr:department><gtr:description>Advanced Immunization Technologies (ADITEC)</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>8FBFFE28-DB8E-4669-B309-6EB7354FB97A</gtr:id><gtr:outcomeId>HEYLTn3JSHJ</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>268000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Capital Equipment Priorities Award</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>59CC82CA-1701-4095-BA8F-30EB4D3CB452</gtr:id><gtr:outcomeId>56d6cfe274ce71.28275491</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>115000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Radcliffe Department of Medicine</gtr:department><gtr:description>RDM Prize Studentship</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>33B6FD56-234C-47EB-90AA-6C4B3983CB9D</gtr:id><gtr:outcomeId>544620ddd5e644.36627586</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>380000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>European Seventh Framework Council - Advanced Immunization Technologies (ADITEC)</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>European Research Council (ERC)</gtr:fundingOrg><gtr:id>9DA38386-0571-4F9F-A97E-F8BA6A674DA9</gtr:id><gtr:outcomeId>5450d34b5dfa79.75859542</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>263000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Capital Bid</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>F49B8D9C-9805-4327-91F0-8E17FBDF6A13</gtr:id><gtr:outcomeId>544622773e4f40.75174864</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Studentship</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>D0AEB814-BD56-421D-BEB7-7A01D306F0F0</gtr:id><gtr:outcomeId>5446212d566166.51959140</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIH (Novel lysosome pathways in infection)</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>B4722880-4C4C-4986-B3AD-0AAE9C9052BE</gtr:id><gtr:outcomeId>p16t6Be7d4N</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>975000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cancer Research UK Programme Grant</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>0DD2E33C-A000-41DE-8F0A-3FC681971A82</gtr:id><gtr:outcomeId>54461fdd597e44.96823244</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>OCRC Development Fund</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>A8D29C9C-8AC7-45A1-84D2-F59B19FC746C</gtr:id><gtr:outcomeId>54462064c14cf4.10835144</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>44000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ECMC</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>71683EBD-4720-459C-8EEC-B4771AA63F37</gtr:id><gtr:outcomeId>hUmzxWktP3e</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>36000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Capital Award Bid</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>BACE413D-1EB2-4904-92EA-33C21F8E8594</gtr:id><gtr:outcomeId>544623b24388d0.45337986</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Studentship</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>1512135B-FC6A-43C8-A05E-75B1D2A3DDF4</gtr:id><gtr:outcomeId>58c92b48717852.70088077</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>97000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>STREAM - Strategies for Excellence in Immuno-Oncology</gtr:description><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>384744E0-6DDB-4A7B-BA8A-3C4826D38AD7</gtr:id><gtr:outcomeId>56d6f3de6f0967.98525762</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Radcliffe Department of Medicine</gtr:department><gtr:description>RDM Studentship</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>8D924EB2-6D96-4EF2-AB2D-694098560010</gtr:id><gtr:outcomeId>58c929c06dd274.49259008</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>74000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK-MedImmune Alliance</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>D6C34C58-56F0-46BD-B07A-49BA2ED573F6</gtr:id><gtr:outcomeId>58aac36a4154a4.25615904</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>468000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KKLF Equipment Grant</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>The Kay Kendall Leukaemia Fund (KKLF)</gtr:fundingOrg><gtr:fundingRef>KKL1057</gtr:fundingRef><gtr:id>80976014-1B8B-4FE6-9964-6C96A8F3885E</gtr:id><gtr:outcomeId>56d9696fd4d4b4.68756963</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>672000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>European Commission Horizon 2020</gtr:description><gtr:end>2021-03-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>A3A4E580-80C0-4C32-9E69-414E81931C6C</gtr:id><gtr:outcomeId>58aabf86065310.13374268</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>School of Medicine</gtr:department><gtr:description>Oxford Nuffield Medical Fellowship</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>02DDB407-F0C7-4B2D-BB78-93919AA044F1</gtr:id><gtr:outcomeId>58c933c5177684.47055312</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>135000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Marie Curie European Fellowship</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>0509B35D-C6EC-4D69-BE27-8699C197782E</gtr:id><gtr:outcomeId>58c932f4918128.08988982</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2046000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UK Vaccine Network</gtr:description><gtr:end>2019-08-02</gtr:end><gtr:fundingOrg>Department of Health (DH)</gtr:fundingOrg><gtr:id>E94E2C76-ACE4-4C36-A37A-74919C3B5B00</gtr:id><gtr:outcomeId>58aac2d5401757.09628499</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The invention provides immunogenic compositions comprising CARD9 and/or Caspase 1 agonists and methods of using the composition to induce or enhance an immune response.</gtr:description><gtr:grantRef>MC_UU_12010/1</gtr:grantRef><gtr:id>3125D27A-E6E7-44D8-90CA-E68F9621A799</gtr:id><gtr:impact>The methods of the invention may be used to treat or prevent diseases and disorders caused by bacterial infections resulting from infection by, among others, Escherichia coli, Caulobacter crescentus, Pseudomonas aeruginosa, Agrobacterium tumefaciens, Branhamella catarrhalis, Citrobacter diversus, Enterobacter aerogenes, Enterobacter cloacae,</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56d95df5551f55.52752714</gtr:outcomeId><gtr:patentId>WO2014055825A1</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>FORMULATION DE COMPOSANTS MYCOBACT&amp;Eacute;RIENS COMME ADJUVANT POUR INDUIRE DES R&amp;Eacute;PONSES TH17 | A FORMULATION OF MYCOBACTERIAL COMPONENTS AS AN ADJUVANT FOR INDUCING TH17 RESPONSES</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF</gtr:description><gtr:grantRef>MC_UU_12010/1</gtr:grantRef><gtr:id>C6CBFE3C-334F-4123-9306-E11CA9563017</gtr:id><gtr:impact>In this patent, which underpinned my subsequent application to the MRC for a phase I clinical trial, we described the use of and composition of matter of a novel family of iNKT cell agonists</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>173338E92D0</gtr:outcomeId><gtr:patentId>CA2626997A</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Analogs of alpha ceramide and uses thereof</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Analogs of alpha ceramide (IMM47) and uses thereof</gtr:description><gtr:grantRef>MC_UU_12010/1</gtr:grantRef><gtr:id>D19A2404-DD16-4565-A2BD-14FD7C2641FA</gtr:id><gtr:impact>In this patent, which underpinned my subsequent application to the MRC for a phase I clinical trial, we described the use of and composition of matter of a novel family of iNKT cell agonists</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>58c7fcf769eaf6.50195815</gtr:outcomeId><gtr:patentId>6836514.7</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Analogs of alpha ceramide (IMM47) and uses thereof</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention provides liposomes containing nonglycosidic ceramides within their bilayers, and compositions thereof. These liposomes activate murine iNKT cells and induce dendritic cell (DC) maturation, both in vitro and in vivo at an efficacy that is comparable to their corresponding soluble nonglycosidic ceramides. Also provided are methods for treating diseases using the liposomes and compositions of the invention.</gtr:description><gtr:grantRef>MC_UU_12010/1</gtr:grantRef><gtr:id>9AB64ED5-183D-4BCC-A527-32CE916C6201</gtr:id><gtr:impact>no notable impact</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>5459f3d8dbccb2.98619571</gtr:outcomeId><gtr:patentId>13/993,946</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Liposomal formulation of nonglycosidic ceramides and uses thereof</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>xxxxxx</gtr:description><gtr:grantRef>MC_UU_12010/1</gtr:grantRef><gtr:id>C54FCC79-8D4D-43D3-B6C6-C0E4D47A37ED</gtr:id><gtr:impact>xxxxxx</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56d95f5aad38e5.39584445</gtr:outcomeId><gtr:patentId>EP2408819A2</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>ANTICORPS ANTI-PEPTIDE NY-ESO-1 DE TYPE R&amp;Eacute;CEPTEUR DES CELLULES T DE HAUTE AFFINIT&amp;Eacute;, PROC&amp;Eacute;D&amp;Eacute;S, ET LEURS UTILISATIONS | HIGH AFFINITY T-CELL RECEPTOR-LIKE NY-ESO-1 PEPTIDE ANTIBODIES, METHODS, AND USES THEREOF</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Analogs of alpha ceramide (IMM47) and uses thereof</gtr:description><gtr:grantRef>MC_UU_12010/1</gtr:grantRef><gtr:id>A0BA0567-CB3D-4A8F-B767-8B799B8E4C45</gtr:id><gtr:impact>In this patent, which underpinned my subsequent application to the MRC for a phase I clinical trial, we described the use of and composition of matter of a novel family of iNKT cell agonists</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>58c7fdcfd71198.98008727</gtr:outcomeId><gtr:patentId>13/464,299</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Analogs of alpha ceramide (IMM47) and uses thereof</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Analogs of alpha ceramide (IMM47) and uses thereof</gtr:description><gtr:grantRef>MC_UU_12010/1</gtr:grantRef><gtr:id>46EBEDEB-E406-4280-A283-558AA52E8464</gtr:id><gtr:impact>In this patent, which underpinned my subsequent application to the MRC for a phase I clinical trial, we described the use of and composition of matter of a novel family of iNKT cell agonists</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>58c7fd3d05a7e6.74534876</gtr:outcomeId><gtr:patentId>12/083,673</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Analogs of alpha ceramide (IMM47) and uses thereof</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Analogs of alpha ceramide (IMM47) and uses thereof</gtr:description><gtr:grantRef>MC_UU_12010/1</gtr:grantRef><gtr:id>0BED7853-9B7E-4B8C-997C-93B7658605D7</gtr:id><gtr:impact>In this patent, which underpinned my subsequent application to the MRC for a phase I clinical trial, we described the use of and composition of matter of a novel family of iNKT cell agonists</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>58c7fcafa84a53.65522203</gtr:outcomeId><gtr:patentId>CN101331146B</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Analogs of alpha ceramide (IMM47) and uses thereof</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Disclosing a galactosylceramide (a-GalCer) analogs and compostions thereof, methods of activating Invariant Natural Killer T (iNKT) cells using said analogs, methods of treating diseases by activating iNKT cells using said analogs, and combination therapy of said analogs.</gtr:description><gtr:grantRef>MC_UU_12010/1</gtr:grantRef><gtr:id>838548FA-312C-4E4C-86AA-D3E749AFD065</gtr:id><gtr:impact>No subsequent impact</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>QJJeoBKYoiK</gtr:outcomeId><gtr:patentId>WO2013/079687A1</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>iNKT CELL MODULATORS AND METHODS OF USING THE SAME</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Analogs of alpha ceramide (IMM47) and uses thereof</gtr:description><gtr:grantRef>MC_UU_12010/1</gtr:grantRef><gtr:id>0B0A218F-0481-4DDB-8A9E-4336C667E2E5</gtr:id><gtr:impact>In this patent, which underpinned my subsequent application to the MRC for a phase I clinical trial, we described the use of and composition of matter of a novel family of iNKT cell agonists</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>58c7fd7967be69.02105845</gtr:outcomeId><gtr:patentId>13/231,403</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Analogs of alpha ceramide (IMM47) and uses thereof</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>We have secured private funding to develop a new family of immune adjuvants which were identified as a collaboration between the University of Oxford (Cerundolo) and the University of Birmingham (Besra). Experiments in a pre-clinical model have demonstrated the ability of this compound (IMM60) to exert an anti-tumoral effect. We have approached the MHRA to obtain approval for the design and toxicology tests to allow us to use this compound in Stage IV melanoma patients. We anticipate that the trial will start during the first few months of 2017.</gtr:description><gtr:id>15A1B6B4-5457-4B96-A11B-60EC4B40B99D</gtr:id><gtr:impact>We have secured funding from private investors</gtr:impact><gtr:outcomeId>56deaea997dce5.95998512</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>A novel family of NKT Cell Agonists</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>iOx Therapeutics</gtr:companyName><gtr:description>The company is centred around development of the use of NKT cell agonists in cancer patients. The close affiliation with the Ludwig Institute will provide access to GMP grade recombinant tumour antigens, which will be used in combination with proprietary GMP grade NKT cell agonists in the clinic.
We have recently secured funding from the EC (Horizon 2020), with iOx being listed as a co-applicant.</gtr:description><gtr:id>1F3E5A1A-3F06-41FD-BD85-F71997CA83CD</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>56deaf9d540ae4.59621374</gtr:outcomeId><gtr:yearCompanyFormed>2015</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>1B83ED35-53EA-49DA-B5EB-22DA7F6174F9</gtr:id><gtr:title>Role of Activins in Hepcidin Regulation during Malaria.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f74b171beed8655598b3801c6e65ac4"><gtr:id>8f74b171beed8655598b3801c6e65ac4</gtr:id><gtr:otherNames>Spottiswoode N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn><gtr:outcomeId>5a2fd8904d12c6.31988667</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9931D66C-8B35-477E-A6A7-8BC60306D20C</gtr:id><gtr:title>Towards multivalent CD1d ligands: synthesis and biological activity of homodimeric a-galactosyl ceramide analogues.</gtr:title><gtr:parentPublicationTitle>Carbohydrate research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3bc556e8a52dfe9b143535b3a1ef5857"><gtr:id>3bc556e8a52dfe9b143535b3a1ef5857</gtr:id><gtr:otherNames>Jervis PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0008-6215</gtr:issn><gtr:outcomeId>pm_14351_21_22445102</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>542FCEF6-C4F5-46AA-AC36-7883226B42D6</gtr:id><gtr:title>Processing of human toll-like receptor 7 by furin-like proprotein convertases is required for its accumulation and activity in endosomes.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2dd798d753b6242950f4fe4166551ba7"><gtr:id>2dd798d753b6242950f4fe4166551ba7</gtr:id><gtr:otherNames>Hipp MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>pm_53cd4b6d4b6ac2b78</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F62DE89-BD0D-40CF-9E8B-910841BDD434</gtr:id><gtr:title>Chasing flies because time flies.</gtr:title><gtr:parentPublicationTitle>Journal of innate immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/297e60d00493b61bbc3912f6acef33d8"><gtr:id>297e60d00493b61bbc3912f6acef33d8</gtr:id><gtr:otherNames>Herwald H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1662-811X</gtr:issn><gtr:outcomeId>56a0a0c82d69d2.53711809</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCD96ED0-676C-4014-8366-8DDE702BC76D</gtr:id><gtr:title>MR1-Restricted Mucosal-Associated Invariant T Cells and Their Activation during Infectious Diseases.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67f08f07df060c5266f71cbf63bc9e76"><gtr:id>67f08f07df060c5266f71cbf63bc9e76</gtr:id><gtr:otherNames>Howson LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>56a0a0c7cd6265.00428846</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>756E41E3-EC8D-4142-83D7-BAED80C816FF</gtr:id><gtr:title>Synthesis of truncated analogues of the iNKT cell agonist, a-galactosyl ceramide (KRN7000), and their biological evaluation.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b71cc096b28f5d38b81344d4bdd2b9bd"><gtr:id>b71cc096b28f5d38b81344d4bdd2b9bd</gtr:id><gtr:otherNames>Veerapen N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn><gtr:outcomeId>eY5JjyC2rbi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8AECBDE-40D0-472D-B66C-FDF730789DAB</gtr:id><gtr:title>Essential role for autophagy during invariant NKT cell development.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdd7cfa24aca2bdff2a40d8bc27c2f1e"><gtr:id>cdd7cfa24aca2bdff2a40d8bc27c2f1e</gtr:id><gtr:otherNames>Salio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>58aabcbb4875d0.25043876</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56A981DB-B3AE-4F91-BFED-DE0FCE16A7D3</gtr:id><gtr:title>Analysis of B Cell Repertoire Dynamics Following Hepatitis B Vaccination in Humans, and Enrichment of Vaccine-specific Antibody Sequences.</gtr:title><gtr:parentPublicationTitle>EBioMedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cabb825b44455b1fd383f5bf28937ac0"><gtr:id>cabb825b44455b1fd383f5bf28937ac0</gtr:id><gtr:otherNames>Galson JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2352-3964</gtr:issn><gtr:outcomeId>58aabcba8b3507.15453748</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38175CBF-5562-4891-9952-374962B56873</gtr:id><gtr:title>Human autoreactive T cells recognize CD1b and phospholipids.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d47083a7f870923cea9bf716967da545"><gtr:id>d47083a7f870923cea9bf716967da545</gtr:id><gtr:otherNames>Van Rhijn I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>56a0a4dceea429.03714048</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8671E973-9A00-49E4-9BD0-F9554ABB2437</gtr:id><gtr:title>Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07fefc16726e8220ca1003792597d1ee"><gtr:id>07fefc16726e8220ca1003792597d1ee</gtr:id><gtr:otherNames>Nakaya HI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>56a0a5c65a5835.45643304</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C683D77-6AE1-4054-A0CD-32623A506DD0</gtr:id><gtr:title>Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef418c3abca2b48b6e483ead3a61a99d"><gtr:id>ef418c3abca2b48b6e483ead3a61a99d</gtr:id><gtr:otherNames>Bedard M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5a9e77ce574590.04938285</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06678516-22C3-4E23-8152-568503243BFA</gtr:id><gtr:title>Co-delivery of PLGA encapsulated invariant NKT cell agonist with antigenic protein induce strong T cell-mediated antitumor immune responses.</gtr:title><gtr:parentPublicationTitle>Oncoimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b045ced11ecc86a5f60212689717498"><gtr:id>9b045ced11ecc86a5f60212689717498</gtr:id><gtr:otherNames>D?len Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2162-4011</gtr:issn><gtr:outcomeId>58aabcbabd1f97.31749247</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28EFD81E-5CB5-4E3A-8BE6-ADD753F4E311</gtr:id><gtr:title>Erratum to: B-cell repertoire dynamics after sequential hepatitis B vaccination and evidence for cross-reactive B-cell activation.</gtr:title><gtr:parentPublicationTitle>Genome medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cabb825b44455b1fd383f5bf28937ac0"><gtr:id>cabb825b44455b1fd383f5bf28937ac0</gtr:id><gtr:otherNames>Galson JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1756-994X</gtr:issn><gtr:outcomeId>58aabcba3a2822.64658796</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8670EB73-6DA1-4FAD-980B-2738FA267F73</gtr:id><gtr:title>Design, synthesis, and functional activity of labeled CD1d glycolipid agonists.</gtr:title><gtr:parentPublicationTitle>Bioconjugate chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3bc556e8a52dfe9b143535b3a1ef5857"><gtr:id>3bc556e8a52dfe9b143535b3a1ef5857</gtr:id><gtr:otherNames>Jervis PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1043-1802</gtr:issn><gtr:outcomeId>pm_14351_21_23458425</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DEC0EA12-14DD-4ADE-88C2-341B399629F0</gtr:id><gtr:title>CD1d-dependent endogenous and exogenous lipid antigen presentation.</gtr:title><gtr:parentPublicationTitle>Current opinion in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d55e13bb2bca478bf77fd2f78fff1d1"><gtr:id>1d55e13bb2bca478bf77fd2f78fff1d1</gtr:id><gtr:otherNames>McEwen-Smith RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0952-7915</gtr:issn><gtr:outcomeId>56a0a0c856aea5.23452831</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92E32DCA-85EC-414F-91E7-3FEAA604DF12</gtr:id><gtr:title>Intestinal DC in migrational imprinting of immune cells.</gtr:title><gtr:parentPublicationTitle>Immunology and cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac7e26fc7687dfd51f87121e4632ed91"><gtr:id>ac7e26fc7687dfd51f87121e4632ed91</gtr:id><gtr:otherNames>Stock A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0818-9641</gtr:issn><gtr:outcomeId>pm_14351_21_23295361</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E028A229-DB23-47D0-91EF-FCBD9A8B7AED</gtr:id><gtr:title>NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54116faae123c2097a55cead7889d479"><gtr:id>54116faae123c2097a55cead7889d479</gtr:id><gtr:otherNames>Chen JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>pm_14351_21_25081390</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4EFEC13-0986-45EE-BA65-EC58520E2843</gtr:id><gtr:title>Expansion of highly activated invariant natural killer T cells with altered phenotype in acute dengue infection.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5253ccac976e8e8fdf9eba0567d80417"><gtr:id>5253ccac976e8e8fdf9eba0567d80417</gtr:id><gtr:otherNames>Kamaladasa A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>56d964067cb079.74553004</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34DE4E3C-2439-438A-A211-7173F8114FD9</gtr:id><gtr:title>Nanomapping of CD1d-glycolipid complexes on THP1 cells by using simultaneous topography and recognition imaging.</gtr:title><gtr:parentPublicationTitle>Journal of molecular recognition : JMR</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47b2aa54635d1b2061138033a1398eb2"><gtr:id>47b2aa54635d1b2061138033a1398eb2</gtr:id><gtr:otherNames>Duman M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0952-3499</gtr:issn><gtr:outcomeId>pm_14351_21_23836468</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>032FC2AA-72C7-4E5B-9EEA-41F4F9FB3277</gtr:id><gtr:title>High frequency of cytolytic 21-hydroxylase-specific CD8+ T cells in autoimmune Addison's disease patients.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c504c639c42d25b9e7c11205a9dbeedd"><gtr:id>c504c639c42d25b9e7c11205a9dbeedd</gtr:id><gtr:otherNames>Dawoodji A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_14351_21_25063864</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4579877E-957A-4425-9FC2-3CCD0B301B1A</gtr:id><gtr:title>Invariant natural killer T cells are not affected by lysosomal storage in patients with Niemann-Pick disease type C.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb84b09f21c093abb7469985c504cd07"><gtr:id>cb84b09f21c093abb7469985c504cd07</gtr:id><gtr:otherNames>Speak AO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>pm_14351_21_22585405</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5FBB5B4-236D-4FD1-8FF7-A8A043A73FCD</gtr:id><gtr:title>Saposins modulate human invariant Natural Killer T cells self-reactivity and facilitate lipid exchange with CD1d molecules during antigen presentation.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdd7cfa24aca2bdff2a40d8bc27c2f1e"><gtr:id>cdd7cfa24aca2bdff2a40d8bc27c2f1e</gtr:id><gtr:otherNames>Salio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_14351_21_24248359</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F719987F-E157-42C9-B556-DC71A82BBA42</gtr:id><gtr:title>Nutritional Stress Induced by Tryptophan-Degrading Enzymes Results in ATF4-Dependent Reprogramming of the Amino Acid Transporter Profile in Tumor Cells.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/308df9ed4646591061d92bfb2f8f47f6"><gtr:id>308df9ed4646591061d92bfb2f8f47f6</gtr:id><gtr:otherNames>Timosenko E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>58aabcb9e0b7b4.38106458</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C677E07-839A-4DFD-A5F1-30DFCDA8D4F4</gtr:id><gtr:title>The regulatory role of invariant NKT cells in tumor immunity.</gtr:title><gtr:parentPublicationTitle>Cancer immunology research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d55e13bb2bca478bf77fd2f78fff1d1"><gtr:id>1d55e13bb2bca478bf77fd2f78fff1d1</gtr:id><gtr:otherNames>McEwen-Smith RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2326-6066</gtr:issn><gtr:outcomeId>56a0a0c8aafcf0.65872713</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA3999DE-ED69-4A54-8F54-83BA381F7FCF</gtr:id><gtr:title>Autophagy Controls Acquisition of Aging Features in Macrophages.</gtr:title><gtr:parentPublicationTitle>Journal of innate immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11955f81f0633569d36221186a4927ab"><gtr:id>11955f81f0633569d36221186a4927ab</gtr:id><gtr:otherNames>Stranks AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1662-811X</gtr:issn><gtr:outcomeId>58aabcbae726a4.58299280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>920FBDC3-F36A-44EE-8835-C44F2A4D98E9</gtr:id><gtr:title>DOCK8 is critical for the survival and function of NKT cells.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e332367c9a2d1abf9cffc91da8ad53b"><gtr:id>8e332367c9a2d1abf9cffc91da8ad53b</gtr:id><gtr:otherNames>Crawford G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_14351_21_23929855</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C8A63D0-94A5-431E-803E-3148427F1B82</gtr:id><gtr:title>In-Depth Assessment of Within-Individual and Inter-Individual Variation in the B Cell Receptor Repertoire.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cabb825b44455b1fd383f5bf28937ac0"><gtr:id>cabb825b44455b1fd383f5bf28937ac0</gtr:id><gtr:otherNames>Galson JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>56a0a0c87a1938.62095893</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FD737F6-BEFF-44A6-957C-AE9253D7DD24</gtr:id><gtr:title>Filaggrin inhibits generation of CD1a neolipid antigens by house dust mite-derived phospholipase.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/491c3e1b512dfea6622f88c5f22471f8"><gtr:id>491c3e1b512dfea6622f88c5f22471f8</gtr:id><gtr:otherNames>Jarrett R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>56d96498452918.65738994</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9640328-045F-4BA8-B793-9C591FD0C91E</gtr:id><gtr:title>Bee venom processes human skin lipids for presentation by CD1a.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b35c1f191240d89a521fb16991424bd0"><gtr:id>b35c1f191240d89a521fb16991424bd0</gtr:id><gtr:otherNames>Bourgeois EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>56a0a0c93e1ed9.00336240</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6B206C3-759A-4990-AC42-93CADE7174A3</gtr:id><gtr:title>Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/adec6e5baca933e8bfa8fbb64258ba23"><gtr:id>adec6e5baca933e8bfa8fbb64258ba23</gtr:id><gtr:otherNames>Scher JU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>pm_14351_21_24192039</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AEAE965A-54E2-40F4-8038-5E29B051ADCB</gtr:id><gtr:title>Cord factor and peptidoglycan recapitulate the Th17-promoting adjuvant activity of mycobacteria through mincle/CARD9 signaling and the inflammasome.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f742adb6508cef89614298d017cabdb8"><gtr:id>f742adb6508cef89614298d017cabdb8</gtr:id><gtr:otherNames>Shenderov K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_14351_21_23630357</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F0B4CEB-54DA-4B4A-83D9-8BA5BC8F4714</gtr:id><gtr:title>Regulation of Lipid Specific and Vitamin Specific Non-MHC Restricted T Cells by Antigen Presenting Cells and Their Therapeutic Potentials.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdd7cfa24aca2bdff2a40d8bc27c2f1e"><gtr:id>cdd7cfa24aca2bdff2a40d8bc27c2f1e</gtr:id><gtr:otherNames>Salio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>56a0a0c96309f1.81287941</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>369E3552-8901-4BF4-8DC7-D9E13B045679</gtr:id><gtr:title>Kinetics and mechanics of two-dimensional interactions between T cell receptors and different activating ligands.</gtr:title><gtr:parentPublicationTitle>Biophysical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a0e94d1951bdc0c24b6d4977fd54a5a"><gtr:id>0a0e94d1951bdc0c24b6d4977fd54a5a</gtr:id><gtr:otherNames>Robert P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-3495</gtr:issn><gtr:outcomeId>pm_14351_21_22339861</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A0FF5F6-DDB1-43F6-AAAC-C597B721E856</gtr:id><gtr:title>The actin cytoskeleton modulates the activation of iNKT cells by segregating CD1d nanoclusters on antigen-presenting cells.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6de2737c81a157a81c65fd17e9d448b5"><gtr:id>6de2737c81a157a81c65fd17e9d448b5</gtr:id><gtr:otherNames>Torreno-Pina JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>56d9646728e6b6.40279545</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2FD847DD-A19C-4074-9D21-86C5BA690107</gtr:id><gtr:title>Non-glycosidic compounds can stimulate both human and mouse iNKT cells.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b82391780be83628fc99fe5451faae5"><gtr:id>0b82391780be83628fc99fe5451faae5</gtr:id><gtr:otherNames>Jukes JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>56d96406a12103.66133187</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13083B64-E8E4-48F7-809E-5BD43432A395</gtr:id><gtr:title>Modulation of cancer-specific immune responses by amino acid degrading enzymes.</gtr:title><gtr:parentPublicationTitle>Immunotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/308df9ed4646591061d92bfb2f8f47f6"><gtr:id>308df9ed4646591061d92bfb2f8f47f6</gtr:id><gtr:otherNames>Timosenko E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1750-743X</gtr:issn><gtr:outcomeId>58aabcb9b85e29.51068240</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96104E8A-FC19-4C3A-9710-5353EFB28D0F</gtr:id><gtr:title>T lymphocytes need less than 3 min to discriminate between peptide MHCs with similar TCR-binding parameters.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74df5c84b51c02bff3ba1fbba395c41a"><gtr:id>74df5c84b51c02bff3ba1fbba395c41a</gtr:id><gtr:otherNames>Brodovitch A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>56a0a0c998c334.88974248</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A9AB587-8819-4972-B890-024E218337C8</gtr:id><gtr:title>Snapin promotes HIV-1 transmission from dendritic cells by dampening TLR8 signaling.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e3557d868a6f9d605bbd870b65530e8"><gtr:id>4e3557d868a6f9d605bbd870b65530e8</gtr:id><gtr:otherNames>Khatamzas E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>5a9e77ce0bd706.75842295</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>161AEDFA-AF76-469A-978B-84ED971FD7D3</gtr:id><gtr:title>Globosides but not isoglobosides can impact the development of invariant NKT cells and their interaction with dendritic cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f71c646940318407a3861110bf2de944"><gtr:id>f71c646940318407a3861110bf2de944</gtr:id><gtr:otherNames>Porubsky S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_14351_21_22875802</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>889E03FC-5561-45AA-AEA6-29438E01B856</gtr:id><gtr:title>M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza.</gtr:title><gtr:parentPublicationTitle>JCI insight</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f02aa2ebb10d042b908ae932541a85e1"><gtr:id>f02aa2ebb10d042b908ae932541a85e1</gtr:id><gtr:otherNames>Cole SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2379-3708</gtr:issn><gtr:outcomeId>5a9e77cdcffc93.05318315</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA4B6525-A632-466E-BEDE-7A94006A4CD9</gtr:id><gtr:title>Identification of Bcl-6-dependent follicular helper NKT cells that provide cognate help for B cell responses.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6dd7df21beeebdf22230b26307bee08e"><gtr:id>6dd7df21beeebdf22230b26307bee08e</gtr:id><gtr:otherNames>Chang PP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>pm_14351_21_22120117</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F68DDF0-CF78-41A4-AFC2-712E4D338420</gtr:id><gtr:title>The Processed Amino-Terminal Fragment of Human TLR7 Acts as a Chaperone To Direct Human TLR7 into Endosomes.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2dd798d753b6242950f4fe4166551ba7"><gtr:id>2dd798d753b6242950f4fe4166551ba7</gtr:id><gtr:otherNames>Hipp MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5675e34faafb7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4934CA58-2D3C-41A1-8A72-CC3A800F541F</gtr:id><gtr:title>Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61a8a8769f57bfb80d01cbd83c6b55f8"><gtr:id>61a8a8769f57bfb80d01cbd83c6b55f8</gtr:id><gtr:otherNames>Cheung KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>58aabcba15be83.70843131</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53B75084-17B7-48F1-BB2C-13C3A0D3113C</gtr:id><gtr:title>Autophagy is a critical regulator of memory CD8(+) T cell formation.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fbd22397ad0524c3053776b6d366b48"><gtr:id>5fbd22397ad0524c3053776b6d366b48</gtr:id><gtr:otherNames>Puleston DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>58aabcbb6f2eb9.81576205</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09F7669D-4BBD-4F45-A992-FEBCD440EC7E</gtr:id><gtr:title>Elevated and cross-responsive CD1a-reactive T cells in bee and wasp venom allergic individuals.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a25fe729ac3cfa6c00ed80a3d003c92"><gtr:id>4a25fe729ac3cfa6c00ed80a3d003c92</gtr:id><gtr:otherNames>Subramaniam S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>56a0a4dc952905.92009722</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FF5A615-8795-4FA8-8421-628C4F0B08F1</gtr:id><gtr:title>Amide analogues of CD1d agonists modulate iNKT-cell-mediated cytokine production.</gtr:title><gtr:parentPublicationTitle>ACS chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6fb13f7f6726d418d15c6c07708d5457"><gtr:id>6fb13f7f6726d418d15c6c07708d5457</gtr:id><gtr:otherNames>Wojno J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1554-8929</gtr:issn><gtr:outcomeId>pm_14351_21_22324848</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>694779DF-93C8-4E97-9D71-75036EEB28C5</gtr:id><gtr:title>Biology of CD1- and MR1-restricted T cells.</gtr:title><gtr:parentPublicationTitle>Annual review of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdd7cfa24aca2bdff2a40d8bc27c2f1e"><gtr:id>cdd7cfa24aca2bdff2a40d8bc27c2f1e</gtr:id><gtr:otherNames>Salio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0732-0582</gtr:issn><gtr:outcomeId>pm_14351_21_24499274</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A2B5792-193D-4D70-9598-B51CE364243B</gtr:id><gtr:title>BCR repertoire sequencing: different patterns of B-cell activation after two Meningococcal vaccines.</gtr:title><gtr:parentPublicationTitle>Immunology and cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cabb825b44455b1fd383f5bf28937ac0"><gtr:id>cabb825b44455b1fd383f5bf28937ac0</gtr:id><gtr:otherNames>Galson JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0818-9641</gtr:issn><gtr:outcomeId>56a0a0c803ec19.14308237</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67EE61CD-47E2-45ED-BD22-1ECA54CD678F</gtr:id><gtr:title>Combinatorial HLA-peptide bead libraries for high throughput identification of CD8? T cell specificity.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa6b6c24080c1135d3653d8e343c7a89"><gtr:id>fa6b6c24080c1135d3653d8e343c7a89</gtr:id><gtr:otherNames>Pan X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>pm_14351_21_24309405</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72F52574-6DEC-4D62-81E7-F77631AB942A</gtr:id><gtr:title>Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9fe1d78d9f73909aa0285fb1be6f87e2"><gtr:id>9fe1d78d9f73909aa0285fb1be6f87e2</gtr:id><gtr:otherNames>Mussai F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_14351_21_23733335</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>439A1914-1BA7-4A64-AFE5-2514323F69F3</gtr:id><gtr:title>The location of splenic NKT cells favours their rapid activation by blood-borne antigen.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed032268c749fe13105b28653a67c1d5"><gtr:id>ed032268c749fe13105b28653a67c1d5</gtr:id><gtr:otherNames>Barral P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>pm_14351_21_22505026</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F05B9894-0D99-4168-B456-FCD205977D58</gtr:id><gtr:title>NAADP activates two-pore channels on T cell cytolytic granules to stimulate exocytosis and killing.</gtr:title><gtr:parentPublicationTitle>Current biology : CB</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b1d9c86788c1281ca4ae8c3808452fe"><gtr:id>2b1d9c86788c1281ca4ae8c3808452fe</gtr:id><gtr:otherNames>Davis LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0960-9822</gtr:issn><gtr:outcomeId>pm_14351_21_23177477</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C92A40A3-A62C-4EF3-9C78-80F55065CC38</gtr:id><gtr:title>Cutting edge: Endoplasmic reticulum stress licenses macrophages to produce mature IL-1? in response to TLR4 stimulation through a caspase-8- and TRIF-dependent pathway.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f742adb6508cef89614298d017cabdb8"><gtr:id>f742adb6508cef89614298d017cabdb8</gtr:id><gtr:otherNames>Shenderov K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_14351_21_24489101</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>917E73E3-A00A-4B76-89DF-9B2B4DAD53B1</gtr:id><gtr:title>B-cell repertoire dynamics after sequential hepatitis B vaccination and evidence for cross-reactive B-cell activation.</gtr:title><gtr:parentPublicationTitle>Genome medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cabb825b44455b1fd383f5bf28937ac0"><gtr:id>cabb825b44455b1fd383f5bf28937ac0</gtr:id><gtr:otherNames>Galson JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1756-994X</gtr:issn><gtr:outcomeId>58aabcba5b08b7.14297213</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B254646-7F99-4DEE-B00C-778B201619FA</gtr:id><gtr:title>Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141(+)XCR1+ dendritic cells.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/334bb3fa06ba7049928f293fe6c4d46a"><gtr:id>334bb3fa06ba7049928f293fe6c4d46a</gtr:id><gtr:otherNames>Silk KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn><gtr:outcomeId>pm_53cd4b6d4b60d13e5</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UU_12010/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>